Clinical Value of Spike Protein Antibody in the Diagnosis of SARS-CoV-2 Infection
*Industry Talks Sessions are part of the Omnia Health Live virtual expo. To sign-up for this webinar please register for Omnia Health Live.
Brought by:
Monday 22nd June 2020
09:00AM GMT | 01:00PM GST
Venue: Omnia Health Live - Industry Talks room
Overview
The novel coronavirus COVID-19 pandemic has now claimed hundreds of thousands of lives worldwide. Both molecular tests for active SARS-CoV-2 antigens and serological tests for the presence of antibodies are key tools for identifying affected individuals and for understanding the immune response in those who have been previously infected with coronavirus and have developed antibodies to it.
Building on its strong commitment to the fight against COVID-19, Beckman Coulter has developed new serology assay (SARS-CoV-2 IgG) with the highest level of quality to help reduce social and economic impacts of the COVID-19 outbreak.
The presentation will discuss the current and future role of antibody testing in overcoming the COVID-19 pandemic, the diagnostic value of SARS-CoV-2 spike (S) protein in inducing highly potent neutralizing antibodies, the need for efficiency in SARS-CoV-2 antibody testing, and how governments now beginning to make use of antibody tests data to decide on re-opening the economy and getting employees back to the workplace.
Learning objectives
By the end of the session, participants will learn about:
- Role of serology testing in COVID-19 and the science behind it
- Scientific insights into clinical value of spike protein in COVID-19 testing.
- Current global guidelines and recommendations for SARS-CoV-2 diagnosis
- Analytical performance of the high-quality Access SARS-CoV-2 IgG test.
Target audience
- Lab Technicians/specialists
- Lab Managers
- Lab Supervisors
- Lab Directors
- Pathologists
Speaker
Dr. Moner Ragas, Ph.D.
Regional Scientific Marketing Manager (EMEA)
Beckman Coulter Diagnostics, Dubai, UAE
Dr Ragas has received his Ph.D. in Biomedical Sciences from Wright State University, Ohio. He has gained over 15 years’ experience as a dedicated Biomedical Scientist with wide diverse experience in business and academia and proven track record of conducting translational research aiming at improving the quality of patient care.
Before joining Beckman Coulter, he was a Graduate Research Assistant in the Department of Neuroscience, Cell Biology and Physiology at WSU and worked as an Assistant Professor at the College of Pharmacy, Al Ain University, UAE and later at College of Health Sciences, QU as an Assistant Professor of Pathophysiology in the Master’s degree Program.
Dr Ragas is currently leading and executing strategic scientific educational programs across Emerging Markets and working closely with highly-skilled Scientific & Medical Affairs, Scientific and Product Marketing stakeholders to support evidence generation studies and promote clinical value of Beckman Coulter innovative solutions.
He is a member of the American Heart Association-Stroke Emphasis Group, the American Society for Microbiology, Society for Neuroscience, Miami Valley Chapter and the American Physiological Society.
Dr Ragas has published cutting-edge research in the area of ischemic stroke treatment. The research results could potentially be translated into effective clinical therapies and save people from long-lasting disability. He has been granted the Original Work Award from WSU during his work in a lab that patented a promising method to treat neurodegeneration in ischemic stroke patients.
Industry Talks Sessions are part of the Omnia Health Live virtual expo. To add this session to your calendar please register for Omnia Health Live.
